Director/PDMR Shareholding

RNS Number : 7719Z

Dechra Pharmaceuticals PLC

22 September 2020

 

22 September 2020

Dechra^® Pharmaceuticals PLC

(Dechra or the Company)

LEI: 213800J4UVB5OWG8VX82

Notification and public disclosure of transactions by

persons discharging managerial responsibilities (PDMRs)

The Company announces that on 22 September 2020 the following Directors were granted awards over Ordinary Shares of 1 pence each in the Company under the Dechra 2017 Long Term Incentive Plan:

Name of individual	Director	Type of award	Number of shares subject to award
Ian Page*	Director	LTIP Award - nil cost option	32,128
Paul Sandland	Director	LTIP Award - nil cost option	13,901
Tony Griffin	Director	LTIP Award - conditional award	10,303

* Ian Page has also been granted a tax qualifying option over 926 shares at an exercise price of £32.37 as part of his LTIP award. This tax qualifying option is linked to the nil cost option such that, at the time of exercise, to the extent that there is a gain in the tax qualifying option, the nil cost option will be forfeited to the value of that gain.

The vesting of all the above awards is subject to the achievement of performance targets. In respect of these grants the performance conditions will be determined by reference to the Company's Earnings per Share (EPS) and its Total Shareholder Return (TSR) relative to constituent companies of the FTSE 250 index (excluding investment trusts) over a three year performance period. Both the EPS and TSR elements will be subject to an additional Return on Capital Employed (ROCE) performance condition. If the ROCE performance condition is not met, then the LTIP Awards will lapse in full.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Forms

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Ian Page
2.	Reason for the notification
a)	Position/status	Director
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan
c)	Price(s) and volumes(s)	Nil cost option Price Volume Nil cost award 32,128 Tax qualifying option Price Volume £32.37 (per Ordinary Share exercise price) 926
d)	Aggregated information -  Aggregate volume -  Price	Awards granted over 33,054 Ordinary Shares in total N/A
e)	Date of the transaction	2020-09-22
f)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Paul Sandland
2.	Reason for the notification
a)	Position/status	Director
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Grant of an award over Ordinary Shares under the Company's Long Term Incentive Plan
c)	Price(s) and volumes(s)	Nil cost option Price Volume Nil cost award 13,901
d)	Aggregated information -  Aggregate volume -  Price	N/A
e)	Date of the transaction	2020-09-22
f)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Tony Griffin
2.	Reason for the notification
a)	Position/status	Director
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Grant of an award over Ordinary Shares under the Company's Long Term Incentive Plan
c)	Price(s) and volumes(s)	Conditional award Price Volume Nil cost award 10,303
d)	Aggregated information -  Aggregate volume -  Price	N/A
e)	Date of the transaction	2020-09-22
f)	Place of the transaction	Outside a trading venue

For further information, please contact:

Melanie Hall, Company Secretary 

Telephone number: 01606 814730

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharm aceuticals PLC.

 

END

 

 

DSHKKBBPQBKDCCB